Allogene Therapeutics, maker of allogeneic T cell therapies, has leased a 118,000-square-foot space in Newark, California, to develop a manufacturing facility. The facility’s production processes will meet good manufacturing practice standards and provide the clinical supply and commercial product for Allogene’s cell therapies pending regulatory approval. Currently, the biotech gets its clinical trial supply through a contracting organization – though that should continue to be “a component of the company’s long-term manufacturing strategy.” The lease is expected to commence in March 2020. Learn More